Methoxy polyethylene glycol-epoetin beta, sold under the brand name Mircera, is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anaemia associated with chronic kidney disease.

[medical citation needed] A U.S. Federal Appeals Court ruled in September 2009, that Mircera infringed a patent held by Amgen Inc.

The court refused to lift an injunction entered in the fall of 2008 which barred Roche from selling Mircera in the United States.

[9] Mircera can reportedly replace traditional erythropoietin drugs as a blood doping agent in endurance sports.

[10] In July 2008, Italian bicycle racer Riccardo Riccò was disqualified from the Tour de France after reports that a urine sample tested positive for Mircera.